REPLOT
Phase II Study of REPotrectinib With or Without Fulvestrant in Patients With Hormone Receptor-positive Human Epidermal Growth Factor 2-negative Metastatic Invasive LObular Carcinoma Who Received a Prior Endocrine Therapy in Combination With Cyclin-dependent Kinase 4 and 6 Inhibitor (REPLOT Trial)
- NCT06408168 ↗
- Terminated
- M.D. Anderson Cancer Center
- Focused
We haven't built an HCP commentary report on REPLOT (repotrectinib and fulvestrant in Hormone Receptor-positive Human Epidermal Growth Factor 2-negative) yet. This page shows the registry record and the public commentary we found that names the trial. A report reads that commentary and sets out what clinicians said about the trial, each point linked to its source. How reports are made.
Indexed commentary on REPLOT so far
Podcasts, YouTube videos and X posts we have indexed that name the trial. It is where a report starts, not where it ends: the build searches for more, so finished reports usually cover more than this.
| Channel | Indexed | |
|---|---|---|
| X threads | 3 | |
| YouTube | 2 |
The trial
ClinicalTrials.gov- Official title
- Phase II Study of REPotrectinib With or Without Fulvestrant in Patients With Hormone Receptor-positive Human Epidermal Growth Factor 2-negative Metastatic Invasive LObular Carcinoma Who Received a Prior Endocrine Therapy in Combination With Cyclin-dependent Kinase 4 and 6 Inhibitor (REPLOT Trial)
- Phase
- Phase 2
- Status
- Terminated
- Conditions
- Hormone Receptor-positive Human Epidermal Growth Factor 2-negative; Metastatic Invasive LObular Carcinoma
- Interventions
- Fulvestrant; Repotrectinib
- Arms
- Cohort 1 · Experimental
- Cohort 2 · Experimental
- Enrollment
- 6
- Primary outcomes
- Safety and adverse events (AEs)
- Sponsor
- M.D. Anderson Cancer Center
- Start
- Aug 8, 2024
- Primary completion
- Dec 8, 2025
- Results posted
- No
- Registry record
- NCT06408168 · updated Jan 5, 2026